AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that the Company and its investigators will be presenting Phase 3 SAP301 study results at Euroanaesthesia 2016, which is taking place in London, UK on May 28-30, 2016. In the SAP301 study, patients with moderate-to-severe acute pain following abdominoplasty, hernioplasty or laparoscopic abdominal surgeries were randomized to receive either ARX-04 (sufentanil sublingual 30 mcg tablet) or a placebo sublingual tablet. The study met its primary endpoint with statistically significant pain intensity differences to baseline over the 12-hour study period (SPID12) in favor of ARX-04 (p<0.001). When analyzed by type of surgery, treatment with ARX-04 resulted in a statistically significant benefit over placebo in each surgery type. ARX-04 was well tolerated in the trial, with nausea, headache and vomiting being the most common treatment-emergent adverse events reported.

Details on the presentation time are as follows:

Date: Monday, May 30, 2016 at 12:15 – 1:45pm (local time)
Title: Safety and efficacy of sufentanil sublingual 30 mcg tablets for the treatment of acute pain following outpatient surgery
Authors: Harold Minkowitz, MD of the Memorial Hermann Memorial City Medical Center in Houston, TX; Shankar Lakshman, MD of Lotus Clinical Research in Pasadena, CA; Timothy Melson, MD of the Helen Keller Hospital in Sheffield, AL; David Leiman, MD of the Victory Medical Center in Houston, TX; and AcelRx Pharmaceuticals’ Karen DiDonato, MSN, RN and Pamela P. Palmer, MD PhD

Euroanaesthesia is Europe’s largest annual event showcasing the latest and the most relevant information in the fields of anesthesia, perioperative medicine, intensive care, emergency medicine and pain treatment. (Original Source)

Shares of Acelrx Pharmaceuticals closed yesterday at $3.39. ACRX has a 1-year high of $5.88 and a 1-year low of $2.59. The stock’s 50-day moving average is $3.41 and its 200-day moving average is $3.79.

On the ratings front, Acelrx has been the subject of a number of recent research reports. In a report issued on May 24, Jefferies Co. analyst Hugo Ong reiterated a Buy rating on ACRX, with a price target of $7, which implies an upside of 106.5% from current levels. Separately, on May 3, H.C. Wainwright’s Ed Arce reiterated a Buy rating on the stock .

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Hugo Ong and Ed Arce have a total average return of -5.8% and 9.2% respectively. Ong has a success rate of 20.0% and is ranked #3054 out of 3869 analysts, while Arce has a success rate of 40.9% and is ranked #473.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of therapies for the treatment of actual pain. Its lead product candidate includes ZalvisoTM intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of sufentanil sublingual tablets delivered by the Zalviso System, a needle-free, handheld, patient-administered, pain management system. It is designed to address the problems associated with post-operative intravenous patient-controlled analgesia, or IV PCA. AcelRx Pharmaceuticals was founded by Thomas A. Schreck and Pamela P. Palmer on July 13, 2005 and is headquartered in Redwood City, CA.